Trends in Endocrinology & Metabolism
ReviewmiRNAs and estrogen action
Section snippets
miRNA biogenesis and regulation
The function of 80–93% of the expressed, non-protein-encoding ‘dark matter RNAs’ (excluding rRNA, mRNA, tRNA, and mtRNA) in the human is not yet fully understood [1]. The importance of noncoding RNAs (ncRNAs), which includes short interfering RNAs (siRNAs), microRNAs (miRNAs), and PIWI-interacting RNA (piRNAs), was recently reviewed [2].
miRNA are small (approx. 20–22 nt) ncRNAs that regulate mRNA translation or stability [3]. About half of miRNAs are intragenic, and most are found in the 5′
ERα, not ERβ, interacts with Drosha
ERα interacts with and suppresses Drosha activity in mouse uterine epithelial cells and MCF-7 cells [23] (Figure 1). ERα–Drosha interaction is enhanced by E2 and by ERα interaction with the p68 and p72 RNA helicases in the Drosha complex [23] (Figure 1). p68 and p72 coactivate ERα and increase its transcriptional activity, by interacting with the N terminus of ERα, but not ERβ [45]. The N terminus of ERα also interacts directly with an LXXLL motif in the C terminus of Drosha [23]. Liganded ERα
E2 and miRNA regulation of Dicer and Ago2
The expression and/or activity of Dicer is regulated by the MAPK pathway: phosphorylation of TRBP enhances the production of growth-promoting miRNAs, for example miR-17 and miR-20a, and inhibits let-7 tumor suppressor expression, at least in HeLa cells [48]. E2 rapidly activates the membrane-associated ERαs activities including activating MAPK in a variety of cell lines [49]; however, no one has evaluated the impact of membrane-initiated ERα regulation of Dicer activity. This possibility is
miRNA regulation of ERα
Although several programs predict miRNA target–gene interaction, such as TargetScan [52] and myMIR [53], specific miRNA–mRNA interaction must be confirmed experimentally by cloning the 3′-UTR of the target mRNA 3′ to a luciferase reporter, and then examining if the miRNA of interest reduces luciferase activity, in transiently transfected cells. Ten miRNAs have been identified as bona fide ERα regulators (reviewed in [13], unless cited here): miR-22 [54], miR-206; miR-221, 222; miR-18a, miR-18b,
Altered miRNA expression in breast cancer
Over 400 studies have been published identifying and examining miRNA in breast cancer with most studies using microarray with confirmation of selected changes by real-time PCR. Aberrant patterns of miRNA expression in human breast cancer have been reviewed (e.g. [65]). miRNAs whose expression is increased in tumor cells, often as a result of chromosomal or molecular genomic aberrations, and which inhibit the translational expression of tumor suppressor genes, are called oncomiRNAs or oncomiRs.
Is E2 synthesis and metabolism regulated by miRNAs?
Estrogens (E2, estrone, and estriol) regulate development and homeostasis in a wide variety of tissues including the reproductive tract, bone, vasculature, brain, and breast. Although the sequence of events leading to breast tumor formation are not completely understood, lifetime exposure to estrogens is a major risk factor for breast cancer development [71]. Some studies indicated that E2 is carcinogenic in human breast epithelial cells, perhaps through genotoxic metabolites, such as 4-OH-E2
miRNAs regulating ER activity by repressing coregulator (coactivator/corepressor) expression
ERs regulate gene transcription by recruiting coregulators that modify chromatin structure in a ligand-, gene-, and cell-specific manner [76]. Although miRNAs would be expected to affect estrogen-regulated gene expression by altering coregulator levels, there are only two reports on coregulator regulation by miRNAs directly affecting ER activity. miR-17-5p was found to inhibit translation of the ER coactivator SRC-3/AIB1/NCOA3 [77]. Transfection of CHO-K1 cells with miR-17-5p and ERα inhibited E
Estrogen regulation of miRNA expression
Because of its role in breast cancer, much of what we know about estrogenic regulation of miRNA expression comes from studies of how E2 treatment of breast cancer cell lines affects mature miRNA expression. Although it is likely that estrogens regulate miRNAs by both genomic (transcriptional) and ‘nongenomic’ mechanisms of action, for example plasma membrane ERα or GPR30- associated signaling cascades, investigators are only beginning to examine these pathways. A PubMed search for estrogen and
Global genome binding studies to identify E2-regulated miRNAs
GRO-seq (global nuclear run-on and sequencing) was used to identify the position and orientation of all engaged RNA polymerases (RNA pol I, II, and III) across the genome of MCF-7 cells treated with 100 nM E2 for 10, 60, or 160 min [27]. This study reported that ERα enhancer transcripts were predominately upregulated by E2, whereas the intergenic transcripts [which would include miRNAs and long intergenic noncoding (linc) RNAs] were predominantly downregulated. The authors identified 322
E2 or fulvestrant-regulated miRNA and their bona fide targets
Table S1 lists E2 or fulvestrant (ER antagonist, ICI182780)-regulated mRNAs and their bona fide (experimentally proven) targets. The major caveat is that the relationship between E2 or fulvestrant regulation of the miRNA and the concordant effect of E2 or fulvestrant on the mRNA gene target has rarely been examined, thus providing direction for future research.
miRNAs related to endocrine resistance in breast cancer
Approximately 40% of breast cancer patients are initially responsive to tamoxifen and other endocrine therapies relapse [91]. The mechanisms for acquired endocrine resistance, despite continued ERα expression, are complex [91]. To date, the role of microRNAs in endocrine resistance has been examined by relatively few investigators. miRNA-221/222 are overexpressed in tamoxifen-, fulvestrant-, and tumor necrosis factor (TNF)-resistant MCF-7 cell line derivatives 20, 92, 93 and in ERα negative
Concluding remarks
E2 and 4-OHT stimulate and repress miRNA expression in a cell- and tissue-specific manner through ERα and, possibly, ERβ. Little is known about how other ER ligands affect miRNA expression or how miRNAs may affect the synthesis or metabolism of E2 and other estrogens. Because ERα interacts with components of the miRNA biogenesis pathway, more research is needed to distinguish E2 regulation at the level of pri-miRNA transcription versus miRNA processing and whether transcriptional or
Conflict of interest
None
Acknowledgments
Special thanks to Dr. Barbara J. Clark for her astute reading and comments to improve this review.
References (100)
Estradiol-activated estrogen receptor α does not regulate mature microRNAs in T47D breast cancer cells
J. Steroid Biochem. Mol. Biol.
(2012)Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs
Am. J. Pathol.
(2010)Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions
Cancer Lett.
(2012)Maturation of microRNA is hormonally regulated by a nuclear receptor
Mol. Cell
(2009)Suppression of LPS-induced IFNgamma and nitric oxide in splenic lymphocytes by select estrogen-regulated miRNA: a novel mechanism of immune modulation
Blood
(2008)A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells
Cell
(2011)Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells
Cancer Lett.
(2011)Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling
Cell
(2009)Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets
Cell
(2005)Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma
Cancer Lett.
(2012)